Efficacy of pre-operative stereotactic radiosurgery followed by surgical resection and correlative radiobiological analysis for patients with 1–4 brain metastases: study protocol for a phase II trial

• Main Authors: Wei X. Huff, Namita Agrawal, Scott Shapiro, James Miller, Charles Kulwin, Mitesh Shah, Jesse J. Savage, Troy Payner, Alexander Vortmeyer, Gordon Watson, Mahua Dey
• Format: Article
• Language: English
• Published: BMC 2018-12-01
• Series: Radiation Oncology
• Subjects: Stereotactic radiosurgery; Brain metastases; Metastases surgery; Immune profiling; Molecular profiling
• Online Access: http://link.springer.com/article/10.1186/s13014-018-1178-8

Abstract Background Stereotactic radiosurgery (SRS) has emerged as a common adjuvant modality used with surgery for resectable brain metastases (BMs). However, the optimal sequence of the multi-modality therapy has not been established. The goal of the study is to evaluate 6-month local control utilizing pre-operative SRS followed by surgical resection for patients with 1–4 brain metastases. Methods This prospective, single arm, phase II trial will recruit patients with up to 4 brain metastases and at least one resectable lesion. All lesions will be treated with SRS and symptomatic lesions will be resected within 1–4 days after SRS. Patients will be monitored for 6-month local control, in-brain progression free survival, distant in-brain failure, rate of leptomeningeal spread, radiation necrosis and overall survival. Additionally, we will also perform correlative radiobiological molecular studies to assess the effect of radiation dosing on the tumor tissue and clinical outcomes. We expect that pre-operative SRS to the gross tumor prior to surgical resection will improve local control and decrease leptomeningeal failure. Discussion Our study is the second prospective trial to investigate the efficacy of pre-operative SRS in the treatment of multiple BMs. In addition, the correlative molecular studies will be the first to investigate early response of BMs at a cellular and genetic level in response to radiation doses and potentially provide molecular prognostic markers for local control and overall survival. Trial registration Clinicaltrials.gov identifier: NCT03398694 (registration date: January 12, 2018).